TG Therapeutics
TGTX
51 hedge funds and large institutions have $80.2M invested in TG Therapeutics in 2014 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 23 increasing their positions, 10 reducing their positions, and 4 closing their positions.
693% more call options, than puts
Call options by funds: $1.74M | Put options by funds: $219K
190% more capital invested
Capital invested by funds: $27.7M → $80.2M (+$52.5M)
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
130% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 10
13% more funds holding
Funds holding: 45 → 51 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$16.7M |
| 2 |
BM
Bridger Management
New York
|
+$5.33M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.18M |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$1.06M |
| 5 |
Morgan Stanley
New York
|
+$650K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$293K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$257K |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$229K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$140K |
| 5 |
Two Sigma Investments
New York
|
-$46K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
51
Sabby Management
Miami Beach,
Florida
| – | -$257K | -66,000 | Closed |
|
|
52
Two Sigma Investments
New York
| – | -$46K | -11,765 | Closed |
|
|
CS
53
Credit Suisse
Zurich,
Switzerland
| – | -$42K | -11,014 | Closed |
|
54
Bank of America
Charlotte,
North Carolina
| – | -$3K | -506 | -95% |
|
TGTX Hedge Fund Activity: Q1 2014 in Review
51 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q1 2014, worth a combined $80.2M — up 190% from $27.7M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new TGTX positions and 4 closed out — a net gain of 6 holders — while 23 added to existing stakes and 10 trimmed.
The largest buyer was JP Morgan Chase, opening a new position worth an estimated $16.7M. The largest seller was DAFNA Capital Management, exiting entirely with an estimated $293K sold.
- 51 institutional investors held TG Therapeutics (TGTX) as of Q1 2014, up from 45 in Q4 2013.
- Funds reported $80.2M of TG Therapeutics stock for Q1 2014, up 190% quarter-over-quarter.
- 10 funds opened new TG Therapeutics positions in Q1 2014 and 4 closed out, a net change of +6 holders.
- The largest TG Therapeutics buyer in Q1 2014 was JP Morgan Chase, an estimated $16.7M added.
- The largest TG Therapeutics seller in Q1 2014 was DAFNA Capital Management, an estimated $293K sold.
Based on aggregated 13F filings for Q1 2014.